How Patient Centricity is a Business Imperative for Life Sciences Companies

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.

Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.

The latest news for pharma industry insiders.

A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.

Currently in Phase III of clinical trials, eneboparatide has shown promise in normalizing key calcium levels and improving bone health in patients with hypoparathyroidism.

The two companies will work together to develop gene therapies in oncology.